KPV
KPV is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone with potent anti-inflammatory properties. It is primarily researched for inflammatory bowel disease, wound healing, and scar reduction.
KPV is a potent anti-inflammatory peptide derived from the C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (alpha-MSH). Composed of lysine-proline-valine, it retains the anti-inflammatory properties of alpha-MSH without causing skin pigmentation.
Overview
KPV is the smallest bioactive fragment of alpha-MSH that retains significant anti-inflammatory activity. First characterized in the 1980s by Hiltz & Lipton (1989), KPV was found to reduce fever in rabbits, though with lower potency than the full alpha-MSH molecule. Decades of subsequent research have revealed that KPV reduces inflammation across a wide variety of disease models while avoiding the pigmentation side effects of its parent peptide. Because KPV is a small peptide, it can be administered through multiple routes including oral, intravenous, subcutaneous, and transdermal delivery.
Mechanism of Action
KPV exerts its anti-inflammatory effects through a mechanism distinct from full-length alpha-MSH. While alpha-MSH binds to melanocortin receptors (MC1R, MC3R, MC4R), studies show that blocking MC3/4 receptors does not abolish KPV's anti-inflammatory effects, indicating an alternative signaling pathway Getting et al. (2003). KPV inhibits NF-kappaB activation and mitogen-activated protein kinase activity, leading to downstream reduction of pro-inflammatory cytokines including TNF-alpha. In the intestine, KPV enters colonic cells via PepT1, a peptide transporter that is upregulated during inflammatory states, which helps explain why KPV is preferentially active in inflamed tissue Dalmasso et al. (2008).
Reconstitution Calculator
KPV
**KPV** is a potent anti-inflammatory peptide derived from the C-terminal tripep
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
General Anti-Inflammatory Activity
Alpha-MSH and its fragments including KPV have been tested across a broad range of inflammatory conditions: fever, contact dermatitis, vasculitis, fibrosis, arthritis, and inflammation of the eyes, brain, lungs, and gastrointestinal tract Brzoska et al. (2008). In all cases, alpha-MSH is the most effective anti-inflammatory, but it causes skin pigmentation. KPV avoids this side effect, and the difference in potency is minimal since the majority of anti-inflammatory effects of alpha-MSH are attributable to the KPV sequence.
The parent molecule appears to be somewhat better at suppressing late-stage inflammatory reactions. In contact dermatitis models, alpha-MSH more effectively prevents allergic inflammatory response at 2 weeks post initial exposure, suggesting it may affect some aspect of immune modulation separate from the immediate inflammatory response Luger & Brzoska (2007).
Scar Formation
KPV reduces the chronic inflammation that leads to hypertrophic scar (e.g., keloid) formation, characterized by widespread macrophage infiltration, TNF immunoreactivity, and neutrophil abundance. Administration of alpha-MSH in this setting leads to smaller scars and less drastic inflammatory response de Souza et al. (2015). Similar effects have been noted in lung and heart tissue, raising hope that KPV could be useful in preventing scarring seen with certain chemotherapy agents Lonati et al. (2013), Colombo et al. (2005), Colombo et al. (2007).
Part of KPV's benefit in reducing scar prominence appears to arise from its ability to modulate collagen metabolism. Alpha-MSH and its analogues suppress IL-8 secretion, which inhibits collagen type 1 production. People prone to keloid formation and hypertrophic scarring have less MC1R mRNA expression on dermal fibroblasts Schiller et al. (2001).
Transdermal Delivery
Research in animal models has shown that KPV can be administered orally, subcutaneously, and via injection without serious side effects. More recently, KPV has been successfully delivered transdermally using iontophoresis across microporated skin Pawar et al. (2017). Different routes of administration affect where the peptide's anti-inflammatory effects are targeted, enabling researchers to direct treatment to different areas within the body.
Intestinal Inflammation
The most significant discovery from KPV research is that the peptide robustly reduces intestinal inflammation. In mouse models of inflammatory bowel disease (IBD), KPV reduces inflammatory infiltrates, myeloperoxidase (MPO) activity, and histological evidence of inflammation. Treated mice recover faster and show more pronounced weight gain than placebo controls Kannengiesser et al. (2008).
Research on delivery mechanisms has revealed that loading KPV onto hyaluronic acid-functionalized nanoparticles directs the peptide to proper locations within the intestine, accelerating mucosal healing and alleviating inflammation through strong downregulation of TNF-alpha Xiao et al. (2017). This nanoparticle approach improves oral bioavailability without changing efficacy, reducing the total dose required for therapeutic effect.
KPV also reduces NF-kappaB and MAPK activity, working in tandem with TNF-alpha inhibition to reduce inflammatory changes in the intestine. Mice treated with KPV show substantially less colonic infiltration and normal colon lengths compared to controls Dalmasso et al. (2008). Notably, KPV appears to only have an effect in the setting of overblown inflammation, with almost no effect in normal tissue. This selectivity is mediated by the PepT1 transporter, which is only expressed in significant quantities in the intestine during inflammatory states.
Wound Healing
Scientists have identified three phases in wound healing: inflammatory, proliferative, and remodeling. Research shows that the majority of cell types across all phases express melanocortin 1 receptor (MC1R) that binds alpha-MSH and its analogues including KPV Brzoska et al. (2008).
KPV offers the anti-inflammatory properties of alpha-MSH without pigment-inducing activity, making it a candidate for improving wound healing while avoiding skin color changes often associated with scar formation. Additionally, KPV inhibits the growth of both Staphylococcus aureus and Candida albicans at physiological concentrations, combining anti-inflammatory activity with antimicrobial activity Cutuli et al. (2000). KPV has also served as a structural model for developing novel anti-fungal therapeutics based on its 3D conformation Masman et al. (2006).
Safety Profile
KPV has demonstrated a favorable safety profile in preclinical studies across multiple routes of administration (oral, subcutaneous, intravenous, transdermal). Unlike its parent molecule alpha-MSH, KPV does not cause skin pigmentation. The peptide's preferential uptake via PepT1 in inflamed intestinal tissue means it has minimal effect on normal tissue, reducing the risk of off-target effects. No serious adverse events have been reported in published animal studies. KPV's anti-inflammatory activity is complemented rather than compromised by antimicrobial properties, distinguishing it from conventional anti-inflammatory agents that may suppress immune defense against infection.
Intestinal Inflammation Studies
In the DSS-induced colitis mouse model, KPV was administered intraperitoneally at doses of 120 nmol/mouse/day for 7 days during acute colitis induction, resulting in significant reduction of disease activity index scores, colonic MPO activity, and histological damage Kannengiesser et al. (2008). A separate study used oral KPV at 53.2 microg/mouse/day loaded onto hyaluronic acid-functionalized polymeric nanoparticles (KPV-HA-NPs, ~200 nm diameter), administered daily by gavage for 5 days in acute DSS colitis and for 26 days in chronic colitis models. Nanoparticle encapsulation reduced the effective dose by approximately 12,000-fold compared to free KPV while maintaining equivalent anti-inflammatory efficacy Xiao et al. (2017).
Anti-Pyretic Studies
The original characterization by Hiltz & Lipton used intracerebroventricular (ICV) injection in rabbits at doses ranging from 5-50 microg. KPV reduced IL-1-induced fever in a dose-dependent manner, though approximately 10-fold higher doses were needed compared to full-length alpha-MSH to achieve equivalent antipyretic effects Hiltz & Lipton (1989).
Transdermal Delivery Studies
Iontophoretic delivery of KPV across laser-microporated porcine skin achieved steady-state flux rates of 1.28 +/- 0.24 microg/cm2/h at 0.5 mA/cm2 current density over 6 hours. Microporation increased passive diffusion by approximately 8-fold, and the combination of microporation with iontophoresis achieved the highest cumulative permeation Pawar et al. (2017).
Antimicrobial Studies
KPV demonstrated concentration-dependent antimicrobial activity against Staphylococcus aureus and Candida albicans at concentrations as low as 10^-12 M, with significant growth inhibition at physiological concentrations (10^-6 M). Killing assays showed 40-60% reduction in colony-forming units after 2-hour incubation Cutuli et al. (2000).
Pharmacokinetic Profile
KPV — Pharmacokinetic Curve
Oral, Subcutaneous injection, TransdermalQuick Start
- Typical Dose
- 200-500 mcg per injection
- Frequency
- 1-2 times daily (once for maintenance, twice for active inflammation)
- Route
- Oral, Subcutaneous injection, Transdermal
- Cycle Length
- 4-8 weeks
- Storage
- Lyophilized: Room temperature. Reconstituted: 2-8°C, refrigerate immediately
Molecular Structure
- Formula
- C16H30N4O4
- Weight
- 342.43 Da
- Length
- 3 amino acids
- CAS
- 67727-97-3
- PubChem CID
- 125672
- Exact Mass
- 342.2267 Da
- LogP
- -3.5
- TPSA
- 139 Ų
- H-Bond Donors
- 4
- H-Bond Acceptors
- 6
- Rotatable Bonds
- 9
- Complexity
- 455
Identifiers (SMILES, InChI)
InChI=1S/C16H30N4O4/c1-10(2)13(16(23)24)19-14(21)12-7-5-9-20(12)15(22)11(18)6-3-4-8-17/h10-13H,3-9,17-18H2,1-2H3,(H,19,21)(H,23,24)/t11-,12-,13-/m0/s1
YSPZCHGIWAQVKQ-AVGNSLFASA-NResearch Indications
Skin Health
Topical KPV reduced psoriatic markers by 60% and improved skin barrier function.
Reduces inflammatory skin conditions without systemic effects.
Gut Health
Demonstrated benefit in Crohn's disease and ulcerative colitis models.
Helps restore intestinal barrier function.
Selective antimicrobial activity preserves beneficial gut bacteria.
Inflammation
Reduces TNF-α and IL-6 through NF-κB pathway inhibition.
May help balance overactive immune responses in autoimmune conditions.
Potential benefits for inflammatory arthritis through cytokine reduction.
Immune Function
Normalizes inflammatory cytokine production
Helps shift from Th1/Th17 to regulatory T cell responses
Maintains antimicrobial defense while reducing inflammation
Research Protocols
subcutaneous Injection
Anti-inflammatory tripeptide derived from alpha-MSH. Particularly studied for gut inflammation.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Week 1 | 200 mcg | Once daily | Week 1 |
| Week 2 | 300 mcg | Once daily | Week 2 |
| Week 3 | 400 mcg | Once daily | Week 3 |
| Full dose | 500 mcg | Once daily | Weeks 4-8+(Cycle: 8-12 weeks, extendable to 16 weeks) |
Reconstitution Guide (10mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 3.33 mg/mL
- For 200 mcg dose: draw 6 units (0.06 mL)
- For 500 mcg dose: draw 15 units (0.15 mL)
- Store reconstituted vial refrigerated at 2-8°C
oral
Oral administration provides direct gut exposure for intestinal conditions.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Gut health support | 200-500mcg | 2-3x daily | —(Route: Mix in water/juice or enteric capsules) |
topical
Topical cream/gel for localized skin inflammation without systemic absorption.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Skin inflammation | 0.1-0.5% cream/gel | 2-3x daily | —(Route: Affected skin areas) |
intranasal Injection
Nasal spray with limited data. May provide systemic effects through nasal absorption.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Systemic anti-inflammatory | 100-300mcg | 2-3x daily (1-2 sprays per nostril) | —(Route: Nasal spray) |
Interactions
Peptide Interactions
KPV + BPC-157 for Wound Healing While no direct combination studies have been published, KPV and BPC-157 target complementary aspects of wound healing.
Loading KPV onto hyaluronic acid (HA)-functionalized nanoparticles exploits the interaction between HA and CD44 receptors, which are overexpressed on inflamed colonic epithelial cells and activated macrophages. This combination achieves dual targeting: PepT1-mediated uptake of KPV plus CD44-media...
What to Expect
What to Expect
Subtle reduction in inflammation, improved energy
Noticeable decrease in inflammatory symptoms
Improved gut function (if applicable), reduced pain/swelling
Significant improvement in inflammatory markers
Sustained benefits, improved quality of life
Safety Profile
Common Side Effects
- Minimal to no side effects reported
- Does not cause immunosuppression like steroids
- No melanin production/tanning effects
- May temporarily reduce inflammation-related symptoms
Contraindications
- Known peptide allergies
- Active severe infections (theoretical)
- Pregnancy or breastfeeding (limited data)
Discontinue If
- Signs of infection (fever, chills) - very rare
- Severe injection site reactions
- Paradoxical inflammation increase
- Allergic reaction symptoms
- Unusual fatigue or weakness
Quality Indicators
What to look for
- High purity >98%
- Clear, colorless solution after reconstitution
- Stable small peptide structure
- Certificate of analysis available
Caution
- pH should be 5.5-7 for optimal stability
Red flags
- Visible particles indicate contamination/degradation
- Yellow coloration indicates oxidation/potency loss
Frequently Asked Questions
References (23)
- [6]Probiotic Combination for IBS
- [7]Post-COVID Inflammatory Syndrome
- [1]KPV in IBD Models (2019)
- [2]Anti-Inflammatory Mechanisms Study (2020)
- [3]Psoriasis/Dermatitis Study (2021)
- [4]Antimicrobial Properties Study (2022)
- [8]
- [9]Kannengiesser et al *Inflamm Inflamm. Bowel Dis. (2008)
- [10]Xiao et al *Mol Mol. Ther. (2017)
- [25]
- [26]
- [27]
- [22]Brzoska et al *Adv Adv. Exp. Med. Biol. (2010)
- [5]
- [13]
- [15]Cutuli et al *J J. Leukoc. Biol. (2000)
- [16]
- [17]de Souza et al *Exp Exp. Dermatol. (2015)
- [18]
- [20]
- [11]Dalmasso et al *Gastroenterology*, 134(1), 166-178 Gastroenterology (2008)
- [12]Richards & Lipton *Peptides*, 5(4), 815-817 Peptides (1984)
- [14]Luger & Brzoska *Ann Ann. Rheum. Dis. (2007)
Klow80 Blend (TB-500 / BPC-157 / GHK-Cu / Ipamorelin)
An 80mg research peptide blend combining TB-500 (10mg), BPC-157 (10mg), GHK-Cu (50mg), and Ipamorelin (10mg) — integrating growth hormone pulsatile release with tissue repair, collagen synthesis, and anti-aging gene modulation for comprehensive regeneration.
Kristagen
Kristagen is a complex peptide bioregulator preparation derived from thymus tissue, developed to support immune function and T-cell-mediated immunity. Research focuses on its potential for countering thymic involution, restoring age-related immune decline, and supporting T-cell differentiation through tissue-specific peptide signaling.